Cardiac Pacemaker Companies | Market Research Future

Top Industry Leaders in the Cardiac Pacemaker Market

Latest Cardiac Pacemaker Companies Update

July 2023: Abbott declared that the AVEIR™ dual chamber (DR) leadless pacemaker system, the inaugural dual chamber leadless pacing system globally, has received approval from the U.S. Food and Drug Administration (FDA). This innovation is designed to assist individuals with irregular or sluggish cardiac rhythms. More than 80% of pacemaker-dependent individuals require pacing in both the right atrium and right ventricle. Therefore, the approval expands leadless pacing accessibility for millions of individuals throughout the United States. Now, with the official introduction of dual chamber leadless pacing, the annals of technological advancements in modern medicine that have fundamentally altered the way physicians treat patients are complete. By introducing a genuine dual chamber leadless pacemaker system, Abbott is granting an unprecedented number of individuals access to the advantages of leadless pacing and enhancing our capacity to treat patients with irregular or sluggish cardiac rhythms.

May 2023: MicroPort, a multinational corporation specializing in cardiac rhythm management, disclosed that it has obtained approval from the US Food and Drug Administration (FDA) for its most recent line of implantable pacemakers, Alizea and Celea, which are the most durable pacemakers currently available in relation to their size. Additionally, the FDA has granted approval for SmartTouch XT, a tablet-based programmer, SmartView Connect bluetooth home monitor, and Vega pacing leads. Alizea and Cele are equipped with the AutoMRI mode, a MicroPort-developed algorithm that enhances the well-being and security of patients undergoing an MRI procedure. To activate the MRI mode, patients need only consult their cardiologist once within ten days prior to the procedure.

List of Cardiac Pacemaker Companies in the market